Delivery Order SPE2DB20D1100-SPE2DB25FC8G3

Award Date 6/11/25
Potential Completion Date 7/3/25
Potential Value $26K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ultomiris 1,100 mg/11 ml vials. The award has a ceiling value of $26,285.85 and a period of performance through April 28, 2025. It is not designated as a set-aside contract. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 through November 2026, which serves as...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $46,826.19, is for the delivery of Ultomiris, a 1,100 mg/11 ml vial medication, with a completion date of February 5, 2024. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the parent...
This federal contract award is for the delivery of Ultomiris, a pharmaceutical product, to the Defense Logistics Agency (DLA). The fixed-price contract, valued at $48,444.54, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of November 7, 2024 and was awarded on October 17, 2024. The contract is a delivery order and does not have a set-aside designation, indicating open competition....
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $4,779.26, is for the delivery of ULTOMIRIS 300 MG/3 ML VIAL 3ML. It is a Firm Fixed Price Delivery Order contract with an ultimate completion date of April 21, 2025. This award is not associated with a set-aside program. Amerisourcebergen Drug Corp is a for-profit organization...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of ULTOMIRIS 1,100 MG/11 ML VIAL 11ML, a pharmaceutical product. The contract has a ceiling value of $52,571.70 and a period of performance extending until May 29, 2025. It is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition....
This federal contract award to AmerisourceBergen Drug Corp's Corporate Office Division is for the delivery of ULTOMIRIS 1,100 MG/11 ML VIAL 11ML, a pharmaceutical product. The contract has a ceiling value of $93,652.38 and an ultimate completion date of July 30, 2024. It was awarded by the Defense Logistics Agency (DLA), a defense agency, on July 9, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of ULTOMIRIS 1,100 MG/11 ML VIAL 11ML medical products. The contract, valued at $192,762.90, was awarded by the Defense Logistics Agency (DLA) Troop Support Medical, a component of the U.S. Department of Defense. The contract is a delivery order type with a firm fixed price pricing structure, and has an ultimate completion date of March 25, 2025....
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $46,826.19, is for the delivery of ULTOMIRIS 1,100 MG/11 ML VIAL 11ML, a specialty pharmaceutical product. This is a delivery order contract with a firm fixed price pricing type, with a period of performance running through November 20, 2024. The contract is not designated as a set-aside and...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Ultomiris, a medication used for the treatment of certain rare blood disorders, with a ceiling value of $46,826.16. The contract is structured as a delivery order with a firm fixed price and an ultimate completion date of September 24, 2024. There is no set-aside designation for this award. AmerisourceBergen, through...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of ULTOMIRIS 1,100 MG/11 ML VIAL 11ML, a specialty pharmaceutical product. The contract has a ceiling value of $26,285.85 and is a firm fixed-price delivery order. The contract does not have a set-aside designation, indicating it was competed on an unrestricted basis. The contract has...
  • SPE2DB20D1100
    Indefinite Delivery Contract
  • SPE2DB20D1100-SPE2DB25FC8G3
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide Ultomiris 300 mg/3 ml vials. The contract has a ceiling value of $26,285.93 and a performance period ending on July 3, 2025. This award is not associated with a set-aside program.

AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00. This prime contract, designated as SPE2DX, provides a comprehensive global pharmaceutical support vehicle with a performance period extending through December 2026. The IDC enables the company to supply a vast range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard.

Generated 9/10/25, 9:55 AM